Core Viewpoint - The company has reported a total accounts receivable of RMB 128 million as of December 31, 2024, with adequate impairment provisions made according to accounting standards, primarily arising from routine business operations [1] Group 1: Accounts Receivable Recovery Efforts - The company has actively pursued the recovery of receivables since the annual report disclosure, implementing tailored strategies based on the debtor's situation [1] - For related party receivables, the company has established a special working mechanism and has successfully recovered a total of RMB 11.0869 million as of November 30, 2025, with legal arbitration initiated for outstanding amounts [1] - For non-related party receivables, the company has reached agreements with cooperative clients, resulting in additional recoveries of RMB 4.4514 million, with ongoing repayment plans [1] Group 2: Measures for Difficult Receivables - For receivables that are harder to recover, the company has legally included relevant debtors in the list of dishonest executors and will closely monitor their asset status for actionable leads [2] - The company has established an "Accounts Receivable Management Committee" led by the finance department to enhance operational fund quality and strengthen internal controls from credit assessment to payment term management [2] Group 3: Future Plans - The company will continue to take all necessary legal and compliant measures to maximize receivable recovery, including ongoing negotiations, enforcing arbitration judgments, and preparing civil lawsuits [2] - Regular progress reports will be provided to the board, and the company will fulfill its information disclosure obligations in accordance with exchange rules [2]
中国医疗集团(08225)：截至11月末已成功收回关联方款项合计1108.69万元